Drug-eluting stents

Coronary disease

Higher percentage of strut coverage in biodegradable polymer DES vs. durable polymer DES. Strut level OCT analyses

Original title: Randomized comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis. Reference:...

solaci - 27 May, 2014

Coronary disease

Angioplasty in sirolimus – eluting stent restenosis is safe and effective beyond the change of drug.

Original title: Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the...

solaci - 6 May, 2014

Chronic Ischemic cardiopathy

Best results of angioplasty with DES guided by IVUS versus angiography only

Original title: Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents to Improve Outcome. A Meta-Analysis. Reference: Jae-Sik Jang et al. J Am...

solaci - 26 February, 2014

Antithrombotic Anticoagulants

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Original title: Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months...

solaci - 25 February, 2014

Coronary disease

3rd generation zotarolimus-eluting stent non- inferior to everolimus

Original title: Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a...

solaci - 13 February, 2014

Chronic Ischemic cardiopathy

Malapposition in drug-eluting stents. Much more common and much less serious than we thought

Original title: Incidences, Predictors, and Clinical Outcomes of Acute and Late Stent Malapposition Detected by Optical Coherence Tomography...

solaci - 28 January, 2014

Acute coronary syndromes

Primary angioplasty with 2nd generation drug-eluting stents

Original title: Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: Network meta-analysis of primary percutaneous coronary...

solaci - 10 December, 2013

Coronary disease

Everolimus -eluting stent to 3 years, most security was the key difference.

Original title: Everolimus-eluting stents in patients undergoing percutaneous coronary Intervention: Final 3-year results of the Clinical Evaluation of...

solaci - 10 December, 2013

Higher percentage of strut coverage in biodegradable polymer DES vs. durable polymer DES. Strut level OCT analyses

Angioplasty in sirolimus – eluting stent restenosis is safe and effective beyond the change of drug.

Best results of angioplasty with DES guided by IVUS versus angiography only

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

3rd generation zotarolimus-eluting stent non- inferior to everolimus

Malapposition in drug-eluting stents. Much more common and much less serious than we thought

Primary angioplasty with 2nd generation drug-eluting stents

Everolimus -eluting stent to 3 years, most security was the key difference.

Últimas Noticias

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Noticias Institucionales

Fellow’s Corner 2026 – Submit Your Clinical Case

Watch Again: Cardiovascular Risk Factors in Women | SOLACI Technicians Webinar

Technical Training in Hemodynamics and Interventional Cardioangiology | SOLACI–CACI

Accesos